LNTH Q1 2026 Earnings
Reported May 7, 2026 at 7:36 AM ET · SEC Source
Q1 26 EPS
$1.46
BEAT +18.78%
Est. $1.23
Q1 26 Revenue
$377.3M
BEAT +6.46%
Est. $354.4M
vs S&P Since Q1 26
+18.7%
BEATING MARKET
LNTH +19.0% vs S&P +0.3%
Market Reaction
Did LNTH Beat Earnings? Q1 2026 Results
Lantheus delivered a clear beat to open fiscal 2026, posting first-quarter revenue of $377.33 million, up 1.2% year over year and ahead of the $354.42 million consensus by 6.46%, while adjusted EPS of $1.46 topped the $1.23 estimate by 18.78%. The he… Read more Lantheus delivered a clear beat to open fiscal 2026, posting first-quarter revenue of $377.33 million, up 1.2% year over year and ahead of the $354.42 million consensus by 6.46%, while adjusted EPS of $1.46 topped the $1.23 estimate by 18.78%. The headline driver was a portfolio in transition: PYLARIFY, the company's flagship PSMA PET imaging agent, faced competitive pressure that trimmed its contribution to $240.92 million, but that softness was offset by Neuraceq's $35.44 million addition following the Life Molecular Imaging acquisition and DEFINITY's 6.8% growth to $84.63 million. A significant regulatory catalyst added further momentum, as the FDA approved PYLARIFY TruVu, a reformulated version designed for manufacturing efficiency, with a phased commercial launch targeted for Q4 2026. Analysts raised price targets following the results, with shares responding positively to the combination of the beat and pipeline progress. Management reaffirmed full-year 2026 guidance of $1.40 billion to $1.45 billion in revenue and adjusted EPS of $5.00 to $5.25, pointing to accelerating growth beginning in 2027.
Key Takeaways
- • Strong DEFINITY sales growth of 6.8% year over year
- • Addition of Neuraceq revenue ($35.4 million) as a new revenue line in neurology
- • Gain on sale of SPECT business boosted GAAP net income
- • Strategic partnerships and other revenue grew 52.1%
LNTH Forward Guidance & Outlook
Lantheus reaffirmed its full-year 2026 guidance: revenue of $1.4 billion to $1.45 billion and adjusted fully diluted EPS of $5.00 to $5.25, unchanged from guidance issued on February 26, 2026. The company plans a phased geographic launch of PYLARIFY TruVu beginning in Q4 2026, is focused on sustaining PSMA PET leadership, expanding its Alzheimer's imaging portfolio, and advancing its prioritized pipeline. Management indicated growth acceleration is expected beginning in 2027 and signaled disciplined capital deployment focused on radiodiagnostics while evaluating value-maximizing alternatives for radiotherapeutic assets.
LNTH YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
LNTH Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our first quarter results demonstrate disciplined execution across the business, with strong performance from PYLARIFY, Neuraceq, and DEFINITY, and continued progress against the priorities that underpin our long-term strategy.”
— Mary Anne Heino, Q1 2026 Earnings Press Release
LNTH Earnings Trends
LNTH vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
LNTH EPS Trend
Earnings per share: estimate vs actual
LNTH Revenue Trend
Quarterly revenue: estimate vs actual
LNTH Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $1.23 | $1.46 | +18.78% | $377.3M | +6.46% |
| Q4 25 BEAT FY | $1.17 | $1.67 | +42.92% | $406.8M | +10.83% |
| FY Full Year | — | $6.08 | — | $1.54B | — |
| Q3 25 BEAT | $1.27 | $1.27 | +0.24% | $384.0M | +5.37% |
| Q2 25 MISS | $1.68 | $1.57 | -6.29% | $378.0M | -2.55% |